Martin Steger
- PhD in 2012 from the University of Zurich
- 2013-2018: Postdoc at the Max-Planck Institute of Biochemistry in Munich (Laboratory of Prof. Matthias Mann)
- 2018-2022: Scientist Targets Validation for molecular glue degraders at Evotec
04/2022-ongoing Scientist MS-based proteomics at the Max-Planck Institute of Biochemistry
Lurong Pan
Dr. Lurong Pan is the Founder and CEO of Ainnocence, a Next Generation Global Biotech. She has extensive drug design and precision medicine research experience using structural biology, computational biophysics and artificial intelligence technologies. She was a Senior Investigator at Global Health Drug Discovery Institute between 2017-2021, was a Research Scientist in Structural Biology and Computational Biology at UAB Medicine between 2013-2015. She is the Director of Computational Science at Integrated System Center, University of Alabama at Birmingham. Dr. Pan received her B.S. in Applied Chemistry from Nanjing University, M.S. in Computer Science from Georgia Tech and Ph.D. in Chemistry from University of Alabama at Birmingham. She is also an IBM certificated big data architect.
Satpal Virdee
Satpal Virdee is Professor of Chemical Biology at the MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee. He studies E3 ligases at the biochemical, structural and cellular level. He has also developed pioneering probe technologies that enable parallel profiling of the activity of potentially hundreds of E3 ligases (activity-based protein profiling). This technology allows the identification of active E3 ligases across diverse tissue types and the discovery of novel E3 classes. He has shown that these can have profound medical importance and are promising targets for diseases with unmet clinical need.
Agnieszka Konopacka
Agnieszka Konopacka is a GSK Associate Fellow and Principal Scientist in the Protein Degradation Group at GSK since 2017. She gained experience in neurotoxicology in the Mossakowski Medical Research Centre in Warsaw during her PhD, followed by a postdoc at Bristol University, in the Laboratories for Integrated Neuroscience and Endocrinology. Looking to apply her expertise to drug discovery she moved to Pfizer Neusentis, where she worked on pain and neurodegenerative disease projects, and later to Horizon Discovery to lead efforts for validation of genetic standards. Currently she works on development and implementation of targeted protein degradation technologies as well as PROTAC projects.
Zuzanna Kozika
Mikolaj Slabicki
Mikołaj Słabicki is a Group Leader in the Cancer Program at the Broad Institute, a member of Dr. Benamin Ebert’s Laboratory, and a Senior Staff Scientist at the Dana-Farber Cancer Institute. Dr. Słabicki employs functional genomics, high-throughput screening, chemical biology, cell biology, and biochemical techniques to identify and characterize new molecular glue degraders and novel mechanisms of targeted protein degradation.
Dr. Słabicki’s research expanded the repertoire of molecular glue degraders and showed that the CDK inhibitor, CR8, induced degradation of cyclin K without a canonical substrate receptor. His research also identified an alternative mechanism of targeted protein degradation, in which a small molecule, BI-3802, induces the highly specific, reversible polymerization and subsequent degradation of the transcription repressor BCL6.
Elizabeth Caine
Stefan Knapp
Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm. In 1999, he joined the Pharmacia (Nerviano Italy) and left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University. From 2008 to 2015 he was a Professor of Structural Biology at Oxford University (UK) and from 2012 to 2015 the director for Chemical Biology at the Target Discovery Institute at Oxford University. He joined Frankfurt University in 2015 as a Professor of Pharmaceutical Chemistry. Since 2017 he is also the CSO of the SGC (Structure Genomics Consortium) node at the Goethe-University Frankfurt. His research interests are unravelling molecular/structural mechanisms of kinase regulation and using high resolution structures, the design of selective kinase inhibitors and inhibitors of protein interactions domains such as bromodomains that are principal readers of the epigenetic acetylation code and E3 ubiquiting ligases.
Yulin Lu
